Antigen Identified By Monoclonal Antikörper Ki-67 (MKI67) Antikörper

Antigen: Antigen Identified By Monoclonal Antibody Ki-67 (MKI67)

Synonyme: KIA, Ki67, Ki-67, D630048A14Rik, MKI67, kia, mki67, MGC132156

Klonalität: Monoklonal (MB67)

Wirt: Maus

Reaktivität: Human

Applikation: Immunhistochemie (IHC)

Produktnummer: ABIN125344

Produktbeschreibung

Weitere Bezeichnung: Ki-67 Antigen

Immunogen: Human recombinant Ki-67 protein corresponding to a 1086bp Ki67 motif-containing fragment.

Format: Ig-fraction

Isotyp: IgG1

Klon: MB67

Spezifität: This antibody reacts with Ki-67 antigen associated with cell proliferation and found throughout the cell cycle (G1, S, G2, M) but absent in resting cells. This antibody is useful in the study of cell proliferation in neoplastic cell populations and with stimulated lymphocytes. It may be used in establishing the growth fraction of neoplasms.

Anwendungen

Applikationshinweise: Titer/Working Dilution: This antibody may be diluted to a titer of 1:25-1:50 in an ABC method. However, depending on the staining conditions employed, we suggest that final dilution should be determined by the user. Staining Protocol: We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user. High temperature treatment of formalin-fixed tissue sections with 10mM citrate buffer, pH 6.0 must be performed prior to the immunostaining. Positive Control: Tonsil. Cellular localization: Nuclear

Konzentration: 100ug/ml approximately

Buffer: This antibody is supplied as purified by protein G chromatography containing sodium azide as preservative.

Lagerung: Store the antibody at 2-8o c. Do not use it beyond the expiration date stated on the label.

Forschungsgebiet: Proliferationsmarker, Zellzyklus

Beschränkungen: Für Forschungszwecke. Als CE-zertifizierter Antikörper in der Europäischen Union für In Vitro Diagnostik (IVD) zugelassen.

Publikationen

Publikationen: Bhattacharya, Tuoth, Durrani et al.: "Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts." in: Neoplasia (New York, N.Y.), Vol. 10, Issue 8, pp. 857-65, 2008 (PubMed).